FRONTIER SCIENCE | PUBLICATIONS

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

Title of Abstract

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

AUTHORS

A. N. J. Tutt; J. Garber; R. D. Gelber; K-A. Phillips; A. Eisen; O. T. Johannsson; P. Rastogi,K.Y.Cui; S-A. Im, R. Yerushalmi; A. M. Brufsky; M. Taboada; G. Rossi; G. Yothers; C. Singer; L. E. Fein; N. Loman; D. Cameron; C. Campbell; C. E. Geyer

PUBLICATION REFERENCE

ESMO Virtual Plenary Abstract | Annals of Oncology | Volume 33 | Issue 5 | Page(s) 566-568 | Publication Year 2022

READ FULL ABSTRACT

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more